HR. 3546In Committee
Prescription Drug Price Relief Act of 2025
Requires HHS to review brand name drug prices for excessive pricing and revoke exclusivity while opening generic and biosimilar competition for drugs found overpriced
Plain-English overview
What this bill does
Requires HHS to review brand name drug prices for excessive pricing and revoke exclusivity while opening generic and biosimilar competition for drugs found overpriced
Key points
- Require annual drug price reviews
- Require manufacturer financial reporting
- Authorize open nonexclusive licenses
- Revoke drug exclusivity rights
Current status
Where it stands
Status
In Committee
Latest action
2025-05-21 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Related context
Topics and policy areas
undefinedHealth